DEF: Sage Therapeutics Seeks Stockholder Approval for Director Elections, Auditor Ratification, Executive Compensation, and ESPP Amendment

Sage Therapeutics is holding its 2025 Annual Meeting of Stockholders to elect directors, ratify the appointment of auditors, approve executive compensation, and amend the Employee Stock Purchase Plan.

Summary

• Sage Therapeutics is convening its 2025 Annual Meeting of Stockholders on June 11, 2025, to address several key proposals.
• Stockholders will vote to elect James M. Frates and George Golumbeski, Ph.D., as Class II directors for terms expiring in 2028.
• The meeting will also include a vote to ratify the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• An advisory vote will be held to approve the compensation paid to the company's named executive officers.
• Stockholders will also consider an amendment to the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan to increase the number of shares authorized for issuance by 500,000 shares, bringing the total to 1,582,000 shares.
• The company is providing access to proxy materials online, aiming to expedite receipt, lower costs, and reduce environmental impact.
• Stockholders of record as of April 16, 2025, are entitled to vote, and the meeting will be held virtually via live webcast.

Sentiment

Score: 7

Explanation: The document is neutral in tone, providing necessary information for stockholders. The company highlights its commitment to good governance and stockholder engagement, which is generally viewed positively.

Positives

• The company is committed to stockholder engagement and incorporates feedback into governance and compensation decisions.
• The company has an independent Chair of the Board, separate from the CEO.
• The company has a robust Code of Business Conduct and Ethics and Corporate Governance Guidelines.
• The company has 100% independence among members of its Audit, Compensation, and Nominating and Corporate Governance Committees.
• The company prohibits insiders from pledging securities or purchasing on margin.
• The company seeks annual advisory approval of executive compensation by stockholders.
• The company has adopted a compensation recovery policy (clawback policy).
• The company maintains a small ecological footprint and is committed to minimizing its carbon footprint.

Risks

• The document does not explicitly detail risks, but inherent risks exist in the biopharmaceutical industry, including clinical trial failures, regulatory hurdles, and market competition.
• The company's success depends on the successful commercialization of ZURZUVAE and the advancement of its pipeline, which are subject to various risks.

Future Outlook

The company intends to continue its stockholder outreach following the filing of the Proxy Statement and the Annual Meeting.

Management Comments

• We believe that effective corporate governance includes active and regular engagement with our stockholders, and we are committed to investing time with our stockholders to increase transparency and gain a better understanding of the practices our stockholders most value.
• We seek to conduct a robust year-round stockholder outreach program to solicit and understand our stockholders perspectives on our executive compensation, corporate governance and disclosure practices, among other matters.

Industry Context

The document highlights the competitive landscape for talent in the biopharmaceutical industry and the importance of equity compensation.

Comparison to Industry Standards

• Over 75% of the companies in our 2025 Peer Group had classified boards.
• Over 75% of companies in our 2025 Peer Group used plurality voting as of the date of our last assessment of peer company voting standards in March 2025.
• As of the date of our last assessment in March 2025, over 75% of our 2025 Peer Group had supermajority voting standards for fundamental corporate changes.

Management Changes

Corporate Governance

Related Party Transactions

• The company recognized revenue from Biogen related to the Biogen Collaboration and License Agreement.

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will shape the company's direction.
• Employees may benefit from the amended Employee Stock Purchase Plan.
• Executive officers' compensation is subject to stockholder approval.
• The company's commitment to corporate governance and ethical conduct impacts all stakeholders.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will continue its stockholder outreach program.
• The Board of Directors and its committees will continue to conduct periodic self-evaluations.

Key Dates

Keywords

stockholders, governance, compensation, directors, ESPP, proxy, meeting, executive, audit, shares, vote, sage